News & Updates

Antiseizure drug yields durable seizure frequency reduction, lowers concomitant medication burden
Antiseizure drug yields durable seizure frequency reduction, lowers concomitant medication burden
12 Nov 2021 byJairia Dela Cruz

In the treatment of adults with uncontrolled focal seizures, the long-term, open-label use of cenobamate appears to produce high rates of sustained 100-percent and ≥90-percent seizure reduction, with parallel decreases in concomitant antiseizure medication (ASM) doses, according to two separate post hoc analyses of a phase III C021 trial.

Antiseizure drug yields durable seizure frequency reduction, lowers concomitant medication burden
12 Nov 2021
Managing comorbidities in rheumatoid arthritis in the new decade
Managing comorbidities in rheumatoid arthritis in the new decade
03 Nov 2021 byProf. Peter Taylor, Prof. Christopher Edwards, Dr. Lian Tsui Yee

Nearly half of all rheumatoid arthritis (RA) patients suffer comorbidity, which has a negative impact on quality of life and mortality. At a recent scientific symposium, Professor Peter Taylor from the University of Oxford in Oxford, UK emphasized the importance of monitoring, preventing, and treating comorbidities in RA while Professor Christopher Edwards from the University Hospital Southampton in Southampton, UK focused on the impact of mental health in RA. The symposium was organized by Fresenius Kabi and held under the auspices of the Singapore Society of Rheumatology. Dr Lian Tsui Yee from Tan Tock Seng Hospital, Singapore chaired the event.

Managing comorbidities in rheumatoid arthritis in the new decade
03 Nov 2021